APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Incretin-Based Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Incretin-Based Drugs Market Outlook and Growth Opportunities 2026

Report ID 174002390421 December 2025196 pages

Choose your research edition.

Industry ResearchIncretin-Based Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Incretin-Based Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Incretin-Based Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Incretin-Based Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Incretin-Based Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Incretin-Based Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Incretin-Based Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Incretin-Based Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Incretin-Based Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Incretin-Based Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Incretin-Based Drugs market include Takeda Pharmaceutical Company, Sanofi, Johnson & Johnson, Novartis, Merck & Co, Eli Lilly and Company, GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Incretin-Based Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Incretin-Based Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Incretin-Based Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Incretin-Based Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Incretin-Based Drugs Segment by Company

Takeda Pharmaceutical Company

Sanofi

Johnson & Johnson

Novartis

Merck & Co

Eli Lilly and Company

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Incretin-Based Drugs Segment by Type

Glucagon-like peptide-1 receptor (GLP-1) agonists

Dipeptidyl Peptidase-4 (DPP-4) inhibitors

Incretin-Based Drugs Segment by Application

Oral Drugs

Injectable Drugs

Incretin-Based Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Incretin-Based Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Incretin-Based Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Incretin-Based Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Incretin-Based Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Incretin-Based Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Incretin-Based Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Incretin-Based Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Incretin-Based Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Incretin-Based Drugs industry.

Chapter 3: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Incretin-Based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Incretin-Based Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Incretin-Based Drugs Industry Trends Table 2. Incretin-Based Drugs Industry Drivers Table 3. Incretin-Based Drugs Industry Opportunities and Challenges Table 4. Incretin-Based Drugs Industry Restraints Table 5. Global Incretin-Based Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Incretin-Based Drugs Revenue Share by Company (2021-2026) Table 7. Global Incretin-Based Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Incretin-Based Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Incretin-Based Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Incretin-Based Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Incretin-Based Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Incretin-Based Drugs Company, Product Type & Application Table 13. Global Incretin-Based Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Incretin-Based Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Glucagon-like peptide-1 receptor (GLP-1) agonists Table 18. Significant Companies of Dipeptidyl Peptidase-4 (DPP-4) inhibitors Table 19. Global Incretin-Based Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Incretin-Based Drugs Sales Volume by Type (2021-2026) & (k units) Table 21. Global Incretin-Based Drugs Sales Volume by Type (2027-2032) & (k units) Table 22. Global Incretin-Based Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Incretin-Based Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Incretin-Based Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Incretin-Based Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Incretin-Based Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Incretin-Based Drugs Sales Value Share by Type (2021-2026) Table 28. Global Incretin-Based Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oral Drugs Table 30. Significant Companies of Injectable Drugs Table 31. Global Incretin-Based Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Incretin-Based Drugs Sales Volume by Application (2021-2026) & (k units) Table 33. Global Incretin-Based Drugs Sales Volume by Application (2027-2032) & (k units) Table 34. Global Incretin-Based Drugs Sales Volume Share by Application (2021-2026) Table 35. Global Incretin-Based Drugs Sales Volume Share by Application (2027-2032) Table 36. Global Incretin-Based Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Incretin-Based Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Incretin-Based Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Incretin-Based Drugs Sales Value Share by Application (2021-2026) Table 40. Global Incretin-Based Drugs Sales Value Share by Application (2027-2032) Table 41. Global Incretin-Based Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Incretin-Based Drugs Sales by Region (2021-2026) & (k units) Table 43. Global Incretin-Based Drugs Sales Market Share by Region (2021-2026) Table 44. Global Incretin-Based Drugs Sales by Region (2027-2032) & (k units) Table 45. Global Incretin-Based Drugs Sales Market Share by Region (2027-2032) Table 46. Global Incretin-Based Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Incretin-Based Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Incretin-Based Drugs Sales Value Share by Region (2021-2026) Table 49. Global Incretin-Based Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Incretin-Based Drugs Sales Value Share by Region (2027-2032) Table 51. Global Incretin-Based Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Incretin-Based Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Incretin-Based Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Incretin-Based Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Incretin-Based Drugs Sales by Country (2021-2026) & (k units) Table 56. Global Incretin-Based Drugs Sales Market Share by Country (2021-2026) Table 57. Global Incretin-Based Drugs Sales by Country (2027-2032) & (k units) Table 58. Global Incretin-Based Drugs Sales Market Share by Country (2027-2032) Table 59. Global Incretin-Based Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Incretin-Based Drugs Sales Value Market Share by Country (2021-2026) Table 61. Global Incretin-Based Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Incretin-Based Drugs Sales Value Market Share by Country (2027-2032) Table 63. Takeda Pharmaceutical Company Company Information Table 64. Takeda Pharmaceutical Company Business Overview Table 65. Takeda Pharmaceutical Company Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Takeda Pharmaceutical Company Incretin-Based Drugs Product Portfolio Table 67. Takeda Pharmaceutical Company Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sanofi Incretin-Based Drugs Product Portfolio Table 72. Sanofi Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Incretin-Based Drugs Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis Incretin-Based Drugs Product Portfolio Table 82. Novartis Recent Development Table 83. Merck & Co Company Information Table 84. Merck & Co Business Overview Table 85. Merck & Co Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck & Co Incretin-Based Drugs Product Portfolio Table 87. Merck & Co Recent Development Table 88. Eli Lilly and Company Company Information Table 89. Eli Lilly and Company Business Overview Table 90. Eli Lilly and Company Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Eli Lilly and Company Incretin-Based Drugs Product Portfolio Table 92. Eli Lilly and Company Recent Development Table 93. GlaxoSmithKline Company Information Table 94. GlaxoSmithKline Business Overview Table 95. GlaxoSmithKline Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. GlaxoSmithKline Incretin-Based Drugs Product Portfolio Table 97. GlaxoSmithKline Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Incretin-Based Drugs Product Portfolio Table 102. AstraZeneca Recent Development Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Incretin-Based Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Incretin-Based Drugs Product Portfolio Table 107. Boehringer Ingelheim Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Incretin-Based Drugs Distributors List Table 111. Incretin-Based Drugs Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Incretin-Based Drugs Product Image Figure 2. Global Incretin-Based Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Incretin-Based Drugs Sales (2021-2032) & (k units) Figure 5. Global Incretin-Based Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Incretin-Based Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Glucagon-like peptide-1 receptor (GLP-1) agonists Image Figure 10. Dipeptidyl Peptidase-4 (DPP-4) inhibitors Image Figure 11. Global Incretin-Based Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Incretin-Based Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Incretin-Based Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Incretin-Based Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Incretin-Based Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Incretin-Based Drugs Sales Value Share by Type (2021-2032) Figure 17. Oral Drugs Image Figure 18. Injectable Drugs Image Figure 19. Global Incretin-Based Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Incretin-Based Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Incretin-Based Drugs Sales Volume Share by Application (2021-2032) Figure 22. Global Incretin-Based Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Incretin-Based Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Incretin-Based Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Incretin-Based Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Incretin-Based Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Incretin-Based Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Incretin-Based Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. North America Incretin-Based Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Incretin-Based Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Incretin-Based Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. South America Incretin-Based Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Incretin-Based Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Incretin-Based Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Incretin-Based Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Incretin-Based Drugs Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Incretin-Based Drugs Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Glucagon-like peptide-1 receptor (GLP-1) agonists
  • Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Applications
  • Oral Drugs
  • Injectable Drugs
Companies covered
  • Takeda Pharmaceutical Company
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co
  • Eli Lilly and Company
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Incretin-Based Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Incretin-Based Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Incretin-Based Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Incretin-Based Drugs Market Dynamics
  1. 2.1 Incretin-Based Drugs Industry Trends
  2. 2.2 Incretin-Based Drugs Industry Drivers
  3. 2.3 Incretin-Based Drugs Industry Opportunities and Challenges
  4. 2.4 Incretin-Based Drugs Industry Restraints
3 Incretin-Based Drugs Market by Company
  1. 3.1 Global Incretin-Based Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Incretin-Based Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Incretin-Based Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Incretin-Based Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Incretin-Based Drugs Company Ranking (2024-2026)
  6. 3.6 Global Incretin-Based Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Incretin-Based Drugs Company Product Type and Application
  8. 3.8 Global Incretin-Based Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Incretin-Based Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Incretin-Based Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Incretin-Based Drugs Market by Type
  1. 4.1 Incretin-Based Drugs Type Introduction
  2. 4.1.1 Glucagon-like peptide-1 receptor (GLP-1) agonists
  3. 4.1.2 Dipeptidyl Peptidase-4 (DPP-4) inhibitors
  4. 4.2 Global Incretin-Based Drugs Sales Volume by Type
  5. 4.2.1 Global Incretin-Based Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Incretin-Based Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Incretin-Based Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Incretin-Based Drugs Sales Value by Type
  9. 4.3.1 Global Incretin-Based Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Incretin-Based Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Incretin-Based Drugs Sales Value Share by Type (2021-2032)
5 Incretin-Based Drugs Market by Application
  1. 5.1 Incretin-Based Drugs Application Introduction
  2. 5.1.1 Oral Drugs
  3. 5.1.2 Injectable Drugs
  4. 5.2 Global Incretin-Based Drugs Sales Volume by Application
  5. 5.2.1 Global Incretin-Based Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Incretin-Based Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Incretin-Based Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Incretin-Based Drugs Sales Value by Application
  9. 5.3.1 Global Incretin-Based Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Incretin-Based Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Incretin-Based Drugs Sales Value Share by Application (2021-2032)
6 Incretin-Based Drugs Regional Sales and Value Analysis
  1. 6.1 Global Incretin-Based Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Incretin-Based Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Incretin-Based Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Incretin-Based Drugs Sales by Region (2027-2032)
  5. 6.3 Global Incretin-Based Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Incretin-Based Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Incretin-Based Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Incretin-Based Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Incretin-Based Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Incretin-Based Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Incretin-Based Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Incretin-Based Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Incretin-Based Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Incretin-Based Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Incretin-Based Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Incretin-Based Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Incretin-Based Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Incretin-Based Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Incretin-Based Drugs Sales Value Share by Country, 2025 VS 2032
7 Incretin-Based Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Incretin-Based Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Incretin-Based Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Incretin-Based Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Incretin-Based Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Incretin-Based Drugs Sales by Country (2027-2032)
  6. 7.4 Global Incretin-Based Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Incretin-Based Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Incretin-Based Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Incretin-Based Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Incretin-Based Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Incretin-Based Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company
  2. 8.1.1 Takeda Pharmaceutical Company Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Incretin-Based Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Incretin-Based Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Incretin-Based Drugs Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Incretin-Based Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck & Co
  26. 8.5.1 Merck & Co Company Information
  27. 8.5.2 Merck & Co Business Overview
  28. 8.5.3 Merck & Co Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co Incretin-Based Drugs Product Portfolio
  30. 8.5.5 Merck & Co Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Incretin-Based Drugs Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Incretin-Based Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Incretin-Based Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Incretin-Based Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Incretin-Based Drugs Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Incretin-Based Drugs Value Chain Analysis
  2. 9.1.1 Incretin-Based Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Incretin-Based Drugs Sales Mode & Process
  6. 9.2 Incretin-Based Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Incretin-Based Drugs Distributors
  9. 9.2.3 Incretin-Based Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst